Abstract

C-reactive protein is currently considered as a prognostic marker of atherosclerotic disease. Its serum levels can help to stratify patients admitted for acute coronary syndrome (ACS). In our data, we investigated whether baseline CRP levels are associated with burden of coronary atherosclerosis assessed by SYNTAX score (SXScore). we enrolled 128 patients with ACS who underwent coronary angiography between January 2015 and November 2015. The patients were divided into tertiles according to the SXScore: low SXScore (≤22), and intermediate-high SXScore (≥23). Subjects in the intermediate-high SXScore tertile had higher serum CRP levels compare to low SXScore tertile patients (17.8±6.4 mg/L versus 10.2±5.3 mg/L, p < 0.001). The mean age of patients and prevalance of diabetes in the intermediate-high SXScore tertile were significantly higher than in the low SXScore tertile (61± 12 versus 57± 10 years; p=0.003 for age, p=0.008 for diabetes). Multivariate logistic regression analysis showed that the strongest predictors of high SXScore were increased serum CRP levels together with multivessel disease, left ventricular ejection fraction (LVEF), and troponin levels. Serum CRP levels on admission in patients with ACS could predict the severity and complexity of coronary atherosclerosis. Thus, increased serum levels of CRP were one of the strong predictors of high SXScore in ACS patients. The author hereby declares no conflict of interest

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.